Literature DB >> 8983974

Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic and inflammatory diseases.

N A Sharif1, S X Xu, P E Magnino, I H Pang.   

Abstract

Dispase-dissociated primary cultures of human conjunctival epithelial (HCE) cells were stimulated with histamine and the generation of inositol phosphates ([3H]IPs) from [3H]phosphoinositide (PI) hydrolysis and the mobilization of intracellular calcium ([Ca2+]i) were studied using ion exchange chromatography and Fura-2 fluorescence techniques, respectively. Histamine (100 microM) maximally stimulated PI turnover in HCE cells by 210 +/- 10% (n = 21) above basal levels and with a potency (EC50) of 3.3 microM (n = 4). Histamine (EC50 = 5.8 microM, n = 3) rapidly mobilized [Ca2+]i which peaked within 10 sec but which was still significantly elevated 20 min after stimulation. The histamine-induced [Ca2+]i responses did not desensitize upon repeated applications of histamine. The effects of histamine (100 microM) on PI turnover and [Ca2+]i were potently antagonized by the H1-antagonists, emedastine (IC50 = 1.6-2.9 nM), triprolidine (IC50 = 3.1 nM) and levocabastine (IC50 = 8 nM), but weakly by the H2-(ranitidine/cimetidine) and H3-(thioperamide) antagonists (IC50s = 10-100 microM). In conclusion, HCE cells have been shown to possess functional H1-histamine receptors that couple to inositol phosphates generation which then mobilize intracellular calcium. These intracellular signaling mechanisms may be intimately linked with the process of inflammatory cytokine secretion from the HCE cells after stimulation by histamine released from the conjunctival mast cells. The current results strongly suggest that the HCE cells are active participants in mediating, and perhaps amplifying, the pro-inflammatory and allergic effects of histamine which is released from conjunctival mast cells during ocular allergic and inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983974     DOI: 10.1006/exer.1996.0105

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

2.  Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles.

Authors:  Aude Pauly; Françoise Brignole-Baudouin; Jean-Marc Guenoun; Luisa Riancho; Patrice Rat; Jean-Michel Warnet; Christophe Baudouin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

Review 3.  Epithelial cells in ocular allergy.

Authors:  Murat Irkeç; Banu Bozkurt
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

Review 4.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Effect of histamine on Ca(2+)-dependent signaling pathways in rat conjunctival goblet cells.

Authors:  Dayu Li; Richard B Carozza; Marie A Shatos; Robin R Hodges; Darlene A Dartt
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-05       Impact factor: 4.799

6.  Human conjunctival epithelial cell responses to platelet-activating factor (PAF): signal transduction and release of proinflammatory cytokines.

Authors:  Najam A Sharif; Shouxi Xu; Peggy E Hellberg; Iok-Hou Pang; Daniel A Gamache; John M Yanni
Journal:  Mol Vis       Date:  2009-06-06       Impact factor: 2.367

7.  Characterization of doxycycline-dependent inducible Simian Virus 40 large T antigen immortalized human conjunctival epithelial cell line.

Authors:  Arisa Mitani; Takeshi Kobayashi; Yasuhito Hayashi; Natsuki Matsushita; Sachi Matsushita; Saori Nakao; Naoko Takahira; Atsushi Shiraishi; Yuichi Ohashi
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.